Literature DB >> 23870315

Mutual antagonism between the Ebola virus VP35 protein and the RIG-I activator PACT determines infection outcome.

Priya Luthra1, Parameshwaran Ramanan, Chad E Mire, Carla Weisend, Yoshimi Tsuda, Benjamin Yen, Gai Liu, Daisy W Leung, Thomas W Geisbert, Hideki Ebihara, Gaya K Amarasinghe, Christopher F Basler.   

Abstract

The cytoplasmic pattern recognition receptor RIG-I is activated by viral RNA and induces type I IFN responses to control viral replication. The cellular dsRNA binding protein PACT can also activate RIG-I. To counteract innate antiviral responses, some viruses, including Ebola virus (EBOV), encode proteins that antagonize RIG-I signaling. Here, we show that EBOV VP35 inhibits PACT-induced RIG-I ATPase activity in a dose-dependent manner. The interaction of PACT with RIG-I is disrupted by wild-type VP35, but not by VP35 mutants that are unable to bind PACT. In addition, PACT-VP35 interaction impairs the association between VP35 and the viral polymerase, thereby diminishing viral RNA synthesis and modulating EBOV replication. PACT-deficient cells are defective in IFN induction and are insensitive to VP35 function. These data support a model in which the VP35-PACT interaction is mutually antagonistic and plays a fundamental role in determining the outcome of EBOV infection.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23870315      PMCID: PMC3875338          DOI: 10.1016/j.chom.2013.06.010

Source DB:  PubMed          Journal:  Cell Host Microbe        ISSN: 1931-3128            Impact factor:   21.023


  47 in total

1.  Modular structure of PACT: distinct domains for binding and activating PKR.

Authors:  G A Peters; R Hartmann; J Qin; G C Sen
Journal:  Mol Cell Biol       Date:  2001-03       Impact factor: 4.272

2.  PACT, a double-stranded RNA binding protein acts as a positive regulator for type I interferon gene induced by Newcastle disease virus.

Authors:  T Iwamura; M Yoneyama; N Koizumi; Y Okabe; H Namiki; C E Samuel; T Fujita
Journal:  Biochem Biophys Res Commun       Date:  2001-03-30       Impact factor: 3.575

3.  PACT, a stress-modulated cellular activator of interferon-induced double-stranded RNA-activated protein kinase, PKR.

Authors:  C V Patel; I Handy; T Goldsmith; R C Patel
Journal:  J Biol Chem       Date:  2000-12-01       Impact factor: 5.157

4.  The Ebola virus VP35 protein functions as a type I IFN antagonist.

Authors:  C F Basler; X Wang; E Mühlberger; V Volchkov; J Paragas; H D Klenk; A García-Sastre; P Palese
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

5.  Interactions of Marburg virus nucleocapsid proteins.

Authors:  S Becker; C Rinne; U Hofsäss; H D Klenk; E Mühlberger
Journal:  Virology       Date:  1998-09-30       Impact factor: 3.616

6.  Three of the four nucleocapsid proteins of Marburg virus, NP, VP35, and L, are sufficient to mediate replication and transcription of Marburg virus-specific monocistronic minigenomes.

Authors:  E Mühlberger; B Lötfering; H D Klenk; S Becker
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

7.  PACT, a protein activator of the interferon-induced protein kinase, PKR.

Authors:  R C Patel; G C Sen
Journal:  EMBO J       Date:  1998-08-03       Impact factor: 11.598

Review 8.  Ebola virus: from discovery to vaccine.

Authors:  Heinz Feldmann; Steven Jones; Hans-Dieter Klenk; Hans-Joachim Schnittler
Journal:  Nat Rev Immunol       Date:  2003-08       Impact factor: 53.106

9.  The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3.

Authors:  Christopher F Basler; Andrea Mikulasova; Luis Martinez-Sobrido; Jason Paragas; Elke Mühlberger; Mike Bray; Hans-Dieter Klenk; Peter Palese; Adolfo García-Sastre
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

10.  Differential roles of human Dicer-binding proteins TRBP and PACT in small RNA processing.

Authors:  Ho Young Lee; Kaihong Zhou; Alison Marie Smith; Cameron L Noland; Jennifer A Doudna
Journal:  Nucleic Acids Res       Date:  2013-05-09       Impact factor: 16.971

View more
  95 in total

1.  Differential Regulation of Interferon Responses by Ebola and Marburg Virus VP35 Proteins.

Authors:  Megan R Edwards; Gai Liu; Chad E Mire; Suhas Sureshchandra; Priya Luthra; Benjamin Yen; Reed S Shabman; Daisy W Leung; Ilhem Messaoudi; Thomas W Geisbert; Gaya K Amarasinghe; Christopher F Basler
Journal:  Cell Rep       Date:  2016-02-11       Impact factor: 9.423

2.  A novel antisense RNA ASPACT confers multi-level suppression of PACT and associated signalling.

Authors:  Yu-Ping Kuo; Chung-Pei Ma; Hui-Wen Chen; Yi-Tung Chen; Yi-Hsuan Lai; Hsuan Liu; Rei-Lin Kuo; Bertrand Chin-Ming Tan
Journal:  RNA Biol       Date:  2019-06-12       Impact factor: 4.652

3.  Predictive and comparative analysis of Ebolavirus proteins.

Authors:  Qian Cong; Jimin Pei; Nick V Grishin
Journal:  Cell Cycle       Date:  2015-07-09       Impact factor: 4.534

Review 4.  Innate immune evasion by filoviruses.

Authors:  Christopher F Basler
Journal:  Virology       Date:  2015-04-03       Impact factor: 3.616

5.  Ebola virus VP35 interaction with dynein LC8 regulates viral RNA synthesis.

Authors:  Priya Luthra; David S Jordan; Daisy W Leung; Gaya K Amarasinghe; Christopher F Basler
Journal:  J Virol       Date:  2015-03-04       Impact factor: 5.103

6.  Impact of Měnglà Virus Proteins on Human and Bat Innate Immune Pathways.

Authors:  Caroline G Williams; Joyce Sweeney Gibbons; Timothy R Keiffer; Priya Luthra; Megan R Edwards; Christopher F Basler
Journal:  J Virol       Date:  2020-06-16       Impact factor: 5.103

7.  Middle east respiratory syndrome coronavirus 4a protein is a double-stranded RNA-binding protein that suppresses PACT-induced activation of RIG-I and MDA5 in the innate antiviral response.

Authors:  Kam-Leung Siu; Man Lung Yeung; Kin-Hang Kok; Kit-San Yuen; Chun Kew; Pak-Yin Lui; Chi-Ping Chan; Herman Tse; Patrick C Y Woo; Kwok-Yung Yuen; Dong-Yan Jin
Journal:  J Virol       Date:  2014-02-12       Impact factor: 5.103

8.  Inhibiting pyrimidine biosynthesis impairs Ebola virus replication through depletion of nucleoside pools and activation of innate immune responses.

Authors:  Priya Luthra; Jacinth Naidoo; Colette A Pietzsch; Sampriti De; Sudip Khadka; Manu Anantpadma; Caroline G Williams; Megan R Edwards; Robert A Davey; Alexander Bukreyev; Joseph M Ready; Christopher F Basler
Journal:  Antiviral Res       Date:  2018-08-23       Impact factor: 5.970

9.  Pathophysiology of Ebola Virus Infection: Current Challenges and Future Hopes.

Authors:  Andrea Rivera; Ilhem Messaoudi
Journal:  ACS Infect Dis       Date:  2015-03-30       Impact factor: 5.084

10.  High-Throughput Minigenome System for Identifying Small-Molecule Inhibitors of Ebola Virus Replication.

Authors:  Megan R Edwards; Colette Pietzsch; Thibaut Vausselin; Megan L Shaw; Alexander Bukreyev; Christopher F Basler
Journal:  ACS Infect Dis       Date:  2015-06-24       Impact factor: 5.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.